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Gentamicin pharmacokinetics during slow daily home hemodi- due to defects in cellular immunity, neutrophil function,
alysis. and complement activation [3, 4]. Therefore, antibiotics
Background. Gentamicin is commonly used in hemodialysis
are often used empirically in an outpatient dialysis setting.patients. Gentamicin pharmacokinetics during traditional he-
Gentamicin, an aminoglycoside antibiotic, may be usedmodialysis have been described. Slow daily home (SDH) hemo-
dialysis (7 to 9 hours a day/6 days a week) use is increasing empirically due to its efficacy against many gram-nega-
due to benefits observed with increased hemodialysis. We de- tive organisms. Gentamicin pharmacokinetics during tra-termined gentamicin pharmacokinetics for SDH hemodialysis
ditional three times a week hemodialysis has been char-patients.
Methods. Eight patients (four male and four female) re- acterized [5–12]; however, the information provided is
ceived a single intravenous dose of 0.6 mg/kg gentamicin post- limited or rendered obsolete, at least in part due to ad-
hemodialysis. Blood samples were collected at 5, 10, 15, 30, vances in dialysis technology over the past 20 years. Oneand 60 minutes after dose. The next day patients underwent
such advancement is slow daily home (SDH) hemodialy-a typical SDH hemodialysis (high-flux F50NR dialyzer) session.
Blood samples were taken at 0, 5, 15, 60, 120, 240, 360, 480 sis, in which patients are dialyzed 6 nights a week for 7
minutes during and 15, 30 and 60 minutes post-hemodialysis. to 9 hours each night. This treatment has been advocated
Baseline and 24-hour urine samples were collected. Pharmaco-
because it has been demonstrated that increased fre-kinetic parameters were calculated assuming a one-compart-
quency and longer duration of treatment results in im-ment model.
Results. Patients were 42.5  13.1 years old (mean  SD). proved patient outcomes [13–17].
Inter-, intra-, and post-hemodialysis collection periods were As gentamicin is frequently used in dialysis patients,
17.0  2.1 hours, 8.1  0.4 hours, and 1.1  0.1 hours, respec-
issues regarding its pharmacokinetics in SDH hemodial-tively. Intra-, and interdialytic gentamicin half-lives were differ-
ysis patients are pertinent. Gentamicin serum concentra-ent (intradialytic, 3.7  0.8 hours; interdialytic, 20.4  4.7
hours; P 0.0001). Hemodialysis clearance accounted for 70.5% tions are routinely monitored to assure maximal efficacy
gentamicin total clearance. Renal clearance correlated with glo- and safety due to its relatively narrow therapeutic index.merular filtration rate (GFR) (renal clearance  1.2 GFR; r2 
Gentamicin pharmacokinetics determined during three0.98; P  0.001). Mean peak and trough of hemodialysis con-
centrations were 1.8 0.6 g/mL and 0.5 0.2 g/mL, respec- times a week, 3 to 4 hour sessions, should not be extrapo-
tively. Post-hemodialysis rebound was 3.1  8.8% at 1 hour. lated to SDH hemodialysis patients. No published studies
Conclusion. Pharmacokinetic model predicts 2.0 to 2.5 mg/kg
exist that specifically address gentamicin dosing in thesedose gentamicin post-hemodialysis would provide peak (1 hour
patients. We characterized gentamicin pharmacokineticpost-dose) and trough (end of SDH hemodialysis session) con-
centrations of 6.0 to 7.5 g/mL and 0.7 to 0.8 g/mL, respec- parameters during a typical SDH hemodialysis session
tively. This would provide adequate coverage for most gram- and from these developed dosing recommendations.negative organisms in SDH hemodialysis patients.
METHODS
Infection remains a leading cause of morbidity and
This study was conducted at an outpatient dialysismortality in end-stage renal disease (ESRD) patients
unit (Dialysis Clinic, Inc., Kansas City, MO, USA) as a[1, 2]. These patients are at an increased risk of infection
prospective, open-label, gentamicin pharmacokinetic study
in ESRD hemodialysis patients. Adult (18 years old orKey words: gentamicin, pharmacokinetics, slow daily home hemodialy-
sis, dosing. older), noninfected, chronic hemodialysis patients were
eligible for participation. Both patients with and without
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Fig. 1. Study design.
were allowed to enter the study after a 2-week washout Blood sampling
period. Patients could not receive any aminoglycoside Five milliliters of venous blood was collected in stan-
antibiotics within 2 weeks prior to their participation. dard blood collection tubes containing no anticoagulant
Patients with stated or documented allergies to amino- (serum separator tubes) at baseline (prior to gentamicin
glycosides were not eligible. Participation of each volun- dose) and at the following times after completion of dose
teer lasted approximately 48 hours. The protocol was administration: 5, 10, 15, 30, and 60 minutes post-genta-
approved by the Adult Health Sciences Review Board micin administration. (Fig. 1)
of the University of Missouri-Kansas City and Dialysis At the next scheduled hemodialysis session, post-void-
Clinic, Inc. All subjects gave written informed consent ing pre-dialysis and post-dialysis weights were recorded.
before participation. Seven milliliters of blood were collected (red-top tubes)
pre-dialysis, at the end of hemodialysis, and 15, 30, andDialysis prescription
60 minutes after dialysis for determination of urea and
All subjects had a standardized 8-hour hemodialysis gentamicin concentration. Five milliliters of blood were
session typical of SDH hemodialysis. Blood flow rate and collected (red-top tubes) at 5, 15, 60, 120, 240, and 360
dialysate flow rates were 200 mL/minute and 300 mL/
minutes into the hemodialysis treatment for gentamicin
minute, respectively. All patients used a high-flux poly-
concentration determination. (Fig. 1) All blood samplessulfone F50 dialysis filter (Fresenius Medical Care, Lex-
were obtained from the arterial line.ington, MA, USA) that has a surface area of 0.5 m2. All
patients used central double-lumen venous catheters for Urine collection
dialysis access.
Nonanuric subjects spontaneously voided immediately
after the first hemodialysis. An aliquot (10 mL) was savedGentamicin administration
and tested to ensure no interfering substances were pres-Subjects received 0.6 mg/kg actual body weight (rounded
ent which would invalidate the assay used for gentamicinto nearest 10 mg) of gentamicin (Schein, Florham Park,
determination in urine. All urine produced up until theNJ, USA) immediately upon completion of a hemodialy-
end of the next scheduled dialysis treatment was col-sis session, after weight (kg) and height (cm) were re-
lected, measured, and an aliquot (10 mL) frozen atcorded. The gentamicin was prepared according to the
70C until the time of assay.manufacturer’s recommendations and was administered
through the in-dwelling venous hemodialysis catheter
Sample preparation and analysisover approximately 30 minutes. The venous catheter was
After being allowed to clot for at least 30 minutes,then flushed with 10 mL saline to ensure that the entire
sera was collected and then frozen to at least 70Cgentamicin dose was given to the patient. After the saline
until analysis. The urine and serum concentrations offlush, the venous catheter was utilized for the duration
of that study for venous sampling. gentamicin were determined by fluorescence polariza-
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Table 1. Patient demographics
Age ABW Height BSA Urine 24-hour GFR Gentamicin
Patient Gender years ESRD diagnosis kg cm m2 mL/24 hours mL/min/1.73 m2 dose mg
A M 40.5 Alport syndrome 73.0 182.9 1.93 0 0 40
B F 33.8 GN 54.7 152.4 1.52 30 0.05 30
C M 45.8 DM 113.1 162.6 2.26 10 0.08 70
D M 68.3 Obstructive uropathy 79.1 188.0 2.03 1350 5.90 50
E M 31.0 GN 153.0 175.3 2.73 100 0.57 90
F F 48.7 HTN 70.4 165.1 1.80 100 0.54 50
G F 46.0 HTN 96.8 167.6 2.12 30 0.30 60
H F 26.1 GN 54.4 157.5 1.54 0 0 30
Mean 42.5 86.8 168.9 1.99 231.4 1.24 52.5
SD 13.1 33.3 12.3 0.40 494.9 2.29 20.5
Abbreviations are: ESRD, end stage renal disease; ABW, actual body weight; BSA, body surface area; GFR, glomerular filtration rate; F, female; M, male; DM,
diabetes mellitus; GN, glomerulonephritis; HTN, hypertension.
Table 2. Gentamicin volume of distribution, elimination ratetion immunoassay (TDx; Abbott Laboratories, Abbott
constants, and corresponding half-lives on and off hemodialysis
Park, IL, USA). The lower limits of quantification for
Patient KHD h1 t1⁄2 HD h KID h1 t1⁄2 ID h Vd L/kggentamicin was 0.3 g/mL. Determination of urine urea
A 0.15 4.6 0.03 26.8 0.24and creatinine and serum urea and creatinine was per-
B 0.23 3.0 0.03 23.6 0.25formed using standard methodology. All assays occurred
C 0.16 4.5 0.05 15.1 0.25
at a central laboratory (Albany Medical Center, Albany, D 0.20 3.5 0.06 12.3 0.29
E 0.14 4.9 0.03 22.9 0.24NY, USA).
F 0.26 2.6 0.03 21.6 0.36
G 0.19 3.8 0.03 21.4 0.32Data analysis H 0.23 3.0 0.04 19.8 0.31
Gentamicin serum concentration results were mod- Mean 0.19 3.7 0.04 20.4 0.28
SD 0.04 0.8 0.01 4.7 0.05eled using PK-Analyst (MicroMath, version 1.0, Salt
Abbreviations are: kel, serum elimination rate; t1⁄2, half-life; Vd, volume ofLake City, UT, USA) pharmacokinetic data analysis
distribution; HD, intradialytic; ID, interdialytic.software. A monoexponential model was assumed and
pharmacokinetic parameters were calculated using stan-
dard formulas. Other calculations performed included lives were significantly different (t1⁄2 inter- and intra-glomerular filtration rate (GFR) and adequacy of dialysis dialytic  20.4  4.7 hours; t1⁄2 hemodialysis  3.7  0.8[urea reduction ratio (URR)] and Kt/V [18, 19]. All hours; P 0.0001). The mean elimination rate constants
equations utilized are provided in the appendix. for interdialytic period (kID) and for intradialytic (kHD)Data are presented as mean  SD. Nonanuric and
were 0.04  0.01 hour1 and 0.19  0.04 hour1, respec-
anuric patient results were compared using Student t
tively. The gentamicin rebound was 3.1%, 4.4%, and
test. Pearson correlations were performed to determine
3.1% at 15, 30, and 60 minutes post-hemodialysis, respec-
an association between GFR and renal clearance and
tively. The amount of gentamicin removed by the hemo-
dialysis adequacy parameters (URR and Kt/V) and gen-
dialysis procedure was 70.5  19.3% administered dose.tamicin hemodialysis clearance. A P value less than 0.05
Gentamicin serum concentrations over time in a typicalwas considered statistically significant. SigmaStat for the
patient (patient F) can be seen in Figure 2.PC (Jandel Scientific, version 1.0, San Rafael, CA, USA)
The mean gentamicin total clearance (during hemodi-was used to perform the statistical calculations.
alysis) was 108.2  43.4 mL/min/1.73 m2. Gentamicin
hemodialysis clearance was 75.9  38.4 mL/min/1.73 m2,
RESULTS accounting for 70.1% of total clearance, respectively.
Summaries of gentamicin clearances and patient hemo-Eight patients were enrolled into the study. The mean
dialysis adequacy are shown in Table 3. The correlationduration on ESRD was 5.6  5.4 years (range, 2 to 19
(r) between GFR and gentamicin renal clearance wasyears). The patient demographics are shown in Table 1.
98% (renal clearance  1.2 GFR; P  0.001, beta Two patients were anuric and five more were oliguric
0.90). The correlation between gentamicin hemodialysis(400 mL urine/24 hours). The mean GFR was 1.24 
clearance and URR was 0.65 (hemodialysis clearance 2.29 mL/min/1.73 m2.
163.8 URR 22.2; P 0.08, beta 0.48). The correlationSummaries of gentamicin pharmacokinetic parame-
between gentamicin hemodialysis clearance and Kt/Vters are shown in Table 2. The mean intra- and interdia-
was 0.61 (hemodialysis clearance  59.26 Kt/V  5.95;lytic times were 17.0  2.1 hours and 8.1  0.4 hours,
respectively. The inter- and intradialytic elimination half- P  0.11, beta  0.49). No significant difference was
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Fig. 2. Gentamicin concentration versus time
profile in a representative patient F following
0.6 mg/kg infusion. Note: The x axis is not a
linear scale.
Table 3. Gentamicin clearances and hemodialysis dialysis adequacy
CLT CLR CLID CLHD CLIT UF
Patient mL/min/1.73 m2 mL/min/1.73 m2 mL/min/1.73 m2 mL/min/1.73 m2 mL/min/1.73 m2 L URR KT/V
A 165.2 21.8 121.6 143.4 0.10 0.66 1.2
B 181.7 0.00 20.5 140.8 161.3 0.00 0.73 1.5
C 70.7 0.01 16.6 37.6 54.2 4.30 0.36 0.6
D 87.6 6.20 17.9 45.5 63.5 1.70 0.59 1.1
E 67.1 0.04 11.7 43.7 55.4 5.40 0.40 0.7
F 118.8 0.04 13.1 92.4 105.6 2.20 0.74 1.6
G 89.1 0.04 13.5 62.1 75.6 0.80 0.66 1.2
H 85.5 11.2 63.2 74.4 1.90 0.75 1.6
Mean 108.2 1.1 15.8 75.9 91.7 2.03 0.61 1.2
SD 43.4 2.5 4.0 38.4 41.0 1.96 0.15 0.4
Abbreviations are: CLT, total body clearance; CLR, renal clearance; CLID, interdialytic clearance; CLHD, hemodialysis clearance; CLIT, intradialytic clearance; UF,
ultrafiltration; URR, urea reduction ratio.
Table 4. Model predicted gentamicin serum concentrations in a concentrations in patient F (70.4 kg) administered 0.6
70 kg individual undergoing typical slow daily home hemodialysis
mg/kg gentamicin. These observed concentrations are
Gentamicin Gentamicin below those considered adequate for pneumonia.
2 mg/kg 2.5 mg/kg
Serum concentration lg/mL
After infusion 6.0 7.5 DISCUSSION
Prior to hemodialysis 3.0 3.7
Gentamicin pharmacokinetics in various hemodialysisAfter hemodialysis 0.7 0.8
Prior to next dose 0.7 0.8 regimens have been well studied. However, the research
performed to date is limited to gentamicin pharmacoki-
netics in three times a week sessions using different he-
observed for any pharmacokinetic parameter between modialysis membranes [5–12]. Presently, one of the ma-
anuric and nonanuric patients. jor advancements in hemodialysis therapy is the use of
Model predicted serum gentamicin concentrations, for SDH hemodialysis as a dialysis modality. These patients
a 70 kg individual post-hemodialysis administration, are dialyze more frequently and use longer treatment times.
shown in Table 4. Model predicted 1-hour post-infusion,
This treatment has been advocated because it has beenpre-hemodialysis, and post-hemodialysis gentamicin se-
demonstrated that increased frequency and longer dura-rum concentrations would be adequate to maintain con-
tion of treatment results in improved patient outcomescentrations for sensitive organisms (serum concentra-
[13–17]. To date there is limited data on gentamicin (ortions between 7.5 g/mL (peak 1-hour post-dose) and
any other drug) pharmacokinetics in the SDH hemodial-0.7 g/mL (trough end of SDH hemodialysis session).
ysis population. The aims of this study were to character-[20] For infectious processes that require higher serum
ize the pharmacokinetics and to model predict an appro-concentrations (e.g., pneumonia), higher doses may be
necessary. Figure 2 illustrates actual gentamicin serum priate dose of gentamicin in SDH hemodialysis patients.
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Gentamicin is eliminated primarily by the kidney either therapeutic levels, if concentration is low, or in-
(95%) in patients with significant renal function. For crease to toxicity, if levels are high. This, in turn, may
those with diminished renal function, extracorporeal re- lead to changes in gentamicin dose and potential toxicity
moval (e.g., hemodialysis) is necessary for elimination. or loss of efficacy, respectively.
Similar to that reported in other hemodialysis pharmaco- It is not surprising that gentamicin renal clearance
kinetic studies, gentamicin pharmacokinetics are mark- correlated strongly to GFR, given that approximately
edly different between the inter- and intradialytic time 95% gentamicin is eliminated renally unchanged [21].
periods. We also showed that SDH hemodialysis avidly Although we found nonsignificant findings in the correla-
removes gentamicin from patients. The measured inter- tions between gentamicin hemodialysis clearance: Kt/V
and intradialytic gentamicin clearance rates were also and gentamicin hemodialysis clearance: URR, the find-
similar to that reported by other investigators [6, 9, 10]. ings were perhaps due to the small sample sizes. The
The similar intradialytic gentamicin clearance rates be- analyses had less than 50% power for each correlation
tween three times a week dialysis and SDH hemodialysis attempted. Three times a week dialysis gentamicin phar-
can be attributed to the differences in dialysate and blood macokinetic studies demonstrated a correlation between
flow rates, time on dialysis, and size of dialysis membrane gentamicin hemodialysis clearance and dialysis adequacy
used in three times a week dialysis and SDH hemodialy-
parameters. [10]
sis patients. Clearance of drug (or any other solute) is
The pharmacokinetic model suggests a gentamicin 2.0dependent upon many variables, including, but not lim-
to 2.5 mg/kg intravenous dose to be given after a SDHited to, the dialysis time, dialyzer size, and flow rates of
hemodialysis session to reach therapeutically adequateblood and dialysate. Three times a week dialysis patients
levels. This will provide serum concentrations betweenare typically exposed to faster blood flow rate and dialy-
7.5g/mL (peak 1-hour post-dose) and 0.7g/mL (troughsate flow rate (300 to 500 mL/minute and 500 to 800 mL/
end of SDH hemodialysis session). These serum concen-minute, respectively), larger dialysis membranes (1.6 to
trations are considered adequate for susceptible organ-1.8 m2), and shorter hemodialysis times (3 to 4 hours).
isms [20]. For infectious processes that require higherThe SDH hemodialysis patients in our study were ex-
serum concentrations to assure adequate tissue penetra-posed to slower blood flow rate and dialysate flow rate
tion (e.g., pneumonia), higher doses may be necessary.(200 mL/minute and 300 mL/minute, respectively), a
Given that gentamicin follows first-order pharmacoki-smaller dialyzer (0.5 m2), and a longer hemodialysis time
netics (i.e., linear), dose increases would be proportional(8 hours).
Of particular interest is the limited gentamicin re- to the desired peak concentration.
bound once the SDH hemodialysis session is completed. Due to the extensive removal by SDH hemodialysis,
In a study of eight patients using three times a week patients would need full-dose gentamicin administered
dialysis utilizing F-80 high-efficiency dialysis membranes, daily after dialysis days to maintain adequate serum con-
greater than 25% rebound occurred [5]. In our present centrations. This dosing regimen is different than that
study of SDH hemodialysis, utilizing F50NR high-effi- for three times a week dialysis patients who only require
ciency dialysis membranes, we observed less than 4% a partial-dose of gentamicin administered after dialysis
rebound. This difference is most likely attributed to the resulting in lower peaks and/or higher troughs [12, 21].
slower dialysate flow rate and blood flow rate in our trial The difference is attributed to the more frequent dialysis
as compared to that reported earlier. In three times a sessions and limited gentamicin rebound in SDH hemo-
week dialysis, the hemodialysis removal rate per unit of dialysis patients. A potential concern of our dosing rec-
time of gentamicin from the systemic circulation is faster ommendation is that it is based on a single-dose study.
than the tissue liberation rate of gentamicin into the
Our patients were not at steady state and the potential
systemic circulation. Thus, rebound occurs once three
for drug accumulation with multiple dosing exists. Thistimes a week dialysis stops. In SDH hemodialysis, the
effect should be minimal given that dialysis occurs daily.slower dialysate flow rate and blood flow rate and smaller
Aminoglycoside associated otovestibular toxicity anddialyzer result in lower gentamicin removal rate. This,
nephrotoxicity are concerns in ESRD patients [22]. Pres-in turn, allows more time for gentamicin to be liberated
ervation of residual renal function in hemodialysis pa-from the tissues and move into the systemic circulation.
tients is associated with lower mortality rates [23]. TheOnce the SDH hemodialysis session stops, the tissue
incidence of toxicity appears to be related to total druggentamicin concentration is near equilibration to that
exposure and duration of therapy [24, 25]. Our gentami-of the systemic circulation, therefore, little rebound is
cin dosing recommendations would allow serum concen-observed. The clinical relevance to the lack of gentamicin
trations to fall to 0.7 to 0.8 g/mL, which is below thatrebound is that clinicians may inappropriately evaluate
considered toxic. Accumulation of gentamicin should notan observed gentamicin concentration. Clinicians may
assume that gentamicin concentrations will increase to occur with the administration of daily hemodialysis.
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ClIT (mL/min/1.73 m2)  A/AUChdCONCLUSION
Equation 9: Hemodialysis clearance (ClHD) was calculated asIn summary, gentamicin needs to be given 2.0 to 2.5
mg/kg intravenously after a hemodialysis session in SDH ClHD (mL/min/1.73 m2)  ClIT – ClID
hemodialysis patients to yield adequate serum concen-
Equation 10: Clearance total (ClT) was calculated astrations. The observed differences in three times a week
ClT (mL/min/1.73 m2)  ClID  ClIT  ClRdialysis and SDH hemodialysis gentamicin pharmacoki-
netics suggest that other studies in SDH hemodialysis Equation 11: Assessment of gentamicin redistribution post-hemodi-
alysis was made for each time point (15, 30, 60 minutes) after hemodial-patients need to be conducted utilizing other medications
ysis and calculated as:and other hemodialysis membranes.
% Redistribution
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Equation 13: Elimination half-life was calculated as
t1/2 (hour)  0.693/KAPPENDIX
Equation 1: Area under the curve (AUC) was calculated by the where K equals either Kid or Khd.
trapezoidal rule. AUC was calculated for interdialytic time period
Equation 14: Estimated glomerular filtration rate (GFR) was calcu-(AUCid) and intradialytic time period (AUChd).
lated from the mean of the following equations:
Equation 2: Elimination rate constant for interdialytic period (Kid)
Urea clearance (mL/min/1.73 m2)was calculated by
Kid (h1)  
urine urea 	 24-hour urine volume
BUN 	 1440ln (60 minutes post-infusion concentration/pre-HD concentration)
timeid where BUN equaled blood urea nitrogen concentration; and
where timeid was the time between 60 minutes post-gentamicin infusion Creatinine clearance (mL/min/1.73 m2)
and initiation of the next hemodialysis session.

urine creatinine 	 24-hour urine volume
Serum creatinine 	 1440
Equation 3: Elimination rate constant for intradialytic period (Khd)
was calculated
Hemodialysis adequacy [Kt/V and urea reduction ratio (URR)]Khd (h1) 
were calculated and correlations investigated between hemodialysis
adequacy and gentamicin ClIT. URR was calculated using the followingln (pre-HD concentration/end of HD concentration
timehd formula
where timehd was the time on dialysis. URR  1 
30-minute post-HD BUN
pre-HD BUN
.
Equation 4: Volume of distribution (Vd) was calculated as
Kt/V was calculated using the mean of the following three formulas
Vd (l/kg) 
Dose
AUCid * Kid (equations 15 to 17) [18, 19]
Equation 15:The Vd was assumed to be constant throughout the study period.
Kt/V   LN [(30 minutes post-HD BUN/pre-HD BUN)  0.03]Equation 5: The renal gentamicin clearance (ClR) was calculated as
 {[4  (3.5 	 30 minutes post-HD BUN/pre-HD BUN]ClR (mL/min/1.73 m2)
	 UF (L)}/post-HD weight (kg)

Urine volume * urine gentamicin concentration
AUCid Equation 16:
where urine volume equaled that which was collected over the interdia-
Kt/V   LN [(30 minutes post-HD BUN/pre-HD BUN)lytic period.
 (0.008 	 time on HD)]  {[4  (3.5Equation 6: The interhemodialysis (intrinsic) clearance (ClID) was
calculated as
	 30 minutes post-HD BUN/pre-HD BUN]
ClID (mL/min/1.73 m2)  Dose/AUCid
	 UF (L)}/post-HD weight (kg)
Equation 7: The amount removed (A) by hemodialysis was calcu-
Equation 17:lated as
Kt/V  (URR 	 2.3)  0.284A (mg)  (pre-HD concentration  end of HD concentration) * Vd
Equation 8: The intra-hemodialysis clearance (ClIT) was calculated as where UF equals ultrafiltration.
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